Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ThromboGenics will underwrite ambitions from €375M ocriplasmin deal with Alcon

This article was originally published in Scrip

Executive Summary

ThromboGenics, the Belgian biotech company, intends to build its ophthalmology franchise with substantial help from Alcon, the eye care specialist subsidiary of Novartis. Alcon has secured the rights to market ocriplasmin outside the US for an upfront payment to the Belgian biotech worth €75 million. With a potential total deal value of €375 million the Belgian biotech could be in line to receive up to€90 million in near term milestones.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts